Oncotarget

Research Papers:

Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients

Mariano Provencio _, David Pérez-Callejo, María Torrente, Paloma Martin, Virginia Calvo, Lourdes Gutiérrez, Fernando Franco, Maria José Coronado, Juan Luis Cruz-Bermúdez, Asunción Martín Ruiz-Valdepeñas, Alberto Cruz-Bermúdez, Margarita Sánchez-Beato, Atocha Romero and Aránzazu García-Grande

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:59408-59416. https://doi.org/10.18632/oncotarget.19722

Metrics: PDF 958 views  |   HTML 1914 views  |   ?  


Abstract

Mariano Provencio1, David Pérez-Callejo1, María Torrente1, Paloma Martin3, Virginia Calvo1, Lourdes Gutiérrez1, Fernando Franco1, Maria José Coronado4, Juan Luis Cruz-Bermúdez5,6, Asunción Martín Ruiz-Valdepeñas1, Alberto Cruz-Bermúdez1, Margarita Sánchez-Beato1, Atocha Romero1 and Aránzazu García-Grande2

1Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain

2Flow Cytometry Core Facility, Hospital Universitario Puerta de Hierro-Majadahonda, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain

3Pathology Department, Molecular Section, Hospital Universitario Puerta de Hierro-Majadahonda, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain

4Confocal Microscopy Core Facility, Hospital Universitario Puerta de Hierro-Majadahonda, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain

5Information Technologies Department, Hospital Universitario Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain

6Universidad Politécnica de Madrid, Madrid, Spain

Correspondence to:

Mariano Provencio, email: mariano.provencio@salud.madrid.org

Keywords: liquid biopsy, non-small-cell lung cancer, circulating tumor cells, ALK-rearrangement, ALK inhibitors

Received: February 21, 2017    Accepted: June 29, 2017    Published: July 31, 2017

ABSTRACT

Background: The identification of anaplastic lymphoma kinase (ALK) rearrangements is found in approximately 5% of non-small-cell lung cancers (NSCLCs). However, the development of liquid biopsies as a diagnostic tool is less developed in these cases. This study investigates the use of CTCs during treatment, together with an extended follow-up to correlate with clinical evolution.

Patients and Methods: A total of 13 patients out of a cohort of 212 patients with lung adenocarcinoma, presented ALK rearrangements (6%) confirmed by tumor biopsy. A total of 60 serial blood samples were collected from these patients who were prospectively enrolled in the study.

Results: All patients had a positive CTC count at baseline (mean = 3). The median follow-up was 9 months (range 1-17 months). Three patients underwent surgery and their CTC counts decreased after the procedure but still remained detectable. After radiotherapy, 3 cases showed an average decrease of 5 CTCs. A total of 6 patients were treated with ALK inhibitors and a partial response was observed in 3 of them, who also presented decreased CTC counts. The other 3 patients presented primary resistance, and their CTC counts were higher than those obtained prior to progression.

Conclusion: We believe that the use of CTCs for dynamic monitoring of NSCLC with ALK rearrangement and to detect disease persistence or recurrence may be a reliable technique. CTC counts may also have potential use to monitor the efficacy of ALK inhibitors, facilitating detection of resistance to treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19722